<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Venous thromboembolism: Anticoagulation after initial management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Venous thromboembolism: Anticoagulation after initial management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Venous thromboembolism: Anticoagulation after initial management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Russell D Hull, MBBS, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory YH Lip, MD, FRCPE, FESC, FACC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James D Douketis, MD, FRCPC, FACP, FCCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H28215396"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Deep vein thrombosis (DVT) and pulmonary embolism (PE) are forms of venous thromboembolism (VTE). VTE has significant morbidity and mortality for patients in the community and in hospital. Anticoagulation is the mainstay of therapy for VTE. The purpose of anticoagulation is the prevention of recurrent thrombosis, embolization, and death, the risk of which is greatest in the first three to six months following the diagnosis.</p><p>Following initial anticoagulation for the first 5 to 10 days, patients with VTE require therapy for a more prolonged period. This topic review will discuss the selection of an anticoagulant, the transition from initial therapy, and the duration and monitoring of long-term anticoagulation. The indications for anticoagulation, an overview of DVT treatment, and details regarding initial and indefinite anticoagulation for patients with VTE are discussed separately. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a> and  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a> and  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p>The approach to anticoagulation outlined in this topic is, in general, consistent with strategies outlined by several international societies including The American College of Chest Physicians, The American College of Physicians, The European Society of Cardiology, The European Respiratory Society, The American Society of Hematology, and others [<a href="#rid1">1-5</a>].</p><p class="headingAnchor" id="H28215402"><span class="h1">NOMENCLATURE</span><span class="headingEndMark"> — </span>For the purposes of discussion in this topic, the following terms apply:</p><p class="bulletIndent1"><span class="glyph">●</span>The term unprovoked deep vein thrombosis (DVT) implies that no identifiable provoking environmental event for DVT is evident [<a href="#rid6">6</a>]. In contrast, a provoked DVT is one that is usually caused by a known event (eg, surgery, hospital admission). VTE events can be provoked by transient major risk factors (ie, major surgery &gt;30 minutes, hospitalization or immobility ≥3 days, caesarian section), transient minor risk factors (minor surgery &lt;30 minutes, hospitalization &lt;3 days, pregnancy, estrogen therapy, reduced mobility ≥3 days) or persistent risk factors. Persistent risk factors include reversible conditions (eg, curable malignancy, inflammatory bowel disease that resolves) and irreversible conditions such as inheritable thrombophilias, chronic heart failure, and metastatic end-stage malignancy. (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initial anticoagulation refers to systemic anticoagulation administered for the first few days (typically up to 10 days) following a diagnosis of acute VTE. Long-term anticoagulant therapy is administered for a finite time beyond the initial period, usually three to six months, and occasionally up to 12 months (ie, there is a scheduled stop date). Extended anticoagulation refers to therapy that is administered indefinitely (ie, no scheduled stop date). (See  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a> and  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral factor Xa and direct thrombin inhibitors have been referred to using a variety of names including newer/novel oral anticoagulants, nonvitamin K antagonist oral anticoagulants (NOAs, NOACs), direct oral anticoagulants (DOACs), and target-specific oral anticoagulants (TOACs, TSOACs) [<a href="#rid7">7</a>]. The term DOACs is more widely used. Throughout this topic, we refer to these agents by their pharmacologic class, factor Xa and direct thrombin inhibitors, or as DOACs. (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p></p><p class="headingAnchor" id="H34600414"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>Details of the indications for anticoagulation for deep vein thrombosis and pulmonary embolism are discussed separately. (See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults"</a> and  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Anticoagulant therapy'</a>.)</p><p class="headingAnchor" id="H28215414"><span class="h1">SELECTION OF AGENT</span><span class="headingEndMark"> — </span>Long-term anticoagulant therapy is administered beyond the initial few days of anticoagulation for a finite period of typically three to six months and up to 12 months in some cases (ie, scheduled stop date). Options for long-term anticoagulation include oral anticoagulants (ie, factor Xa inhibitors, direct thrombin inhibitor, and <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) and parenteral subcutaneous anticoagulants (low molecular weight [LMW] heparin and <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a>). While the factor Xa and thrombin inhibitors are typically preferred, choosing among these options frequently depends upon clinician experience and availability, the risks of bleeding, patient comorbidities and preferences, cost, and convenience  (<a class="graphic graphic_table graphicRef107541" href="/d/graphic/107541.html" rel="external">table 1</a>).</p><p>Patient values and preferences are critical in selecting a long-term agent for anticoagulation in acute VTE. Variations exist in the perceptions of burden by patients. For example, while some patients want to avoid daily injections, others may consider them preferable to weekly international normalized ratio (INR) monitoring [<a href="#rid8">8</a>]. As another example, patients who place a high value on cost may choose <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, while others who place a high value on a lower risk of bleeding may prefer the direct oral anticoagulants (DOACs). (See  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'Patient values and preferences'</a>.)</p><p class="headingAnchor" id="H3738191155"><span class="h2">General population</span><span class="headingEndMark"> — </span>As a general principle, oral agents are typically preferable to parenteral agents. For most nonpregnant patients who do not have severe renal insufficiency or active cancer, we suggest the DOACs, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>, or <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>, rather than <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>  (<a class="graphic graphic_table graphicRef91199" href="/d/graphic/91199.html" rel="external">table 2</a>) and suggest warfarin rather than LMW heparin. Factors that influence agent selection including feasibility of oral administration are discussed below  (<a class="graphic graphic_table graphicRef107541" href="/d/graphic/107541.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factor Xa inhibitors (eg, </strong><strong>rivaroxaban</strong><strong>, </strong><strong>apixaban</strong><strong>, </strong><strong>edoxaban</strong><strong>) and oral direct thrombin inhibitor (ie, </strong><strong>dabigatran</strong><strong>)</strong> – These oral agents are our preferred anticoagulant for most hemodynamically stable, nonpregnant patients who do not have severe renal insufficiency or active cancer  (<a class="graphic graphic_table graphicRef91199" href="/d/graphic/91199.html" rel="external">table 2</a>). While <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> and <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> can be administered as monotherapy, <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a> and <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> are preferably administered following a five day course of heparin (ie, as dual therapy; <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> [UFH] or LMW heparin).</p><p></p><p class="bulletIndent1">Our preference for these agents is based upon their similar efficacy, reduced need for monitoring, and lower bleeding risk profile, when compared with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>. In addition, theoretically patients may spend more time in the therapeutic range with these agents when compared with warfarin. Clinicians should be aware that although the risk of bleeding is lower with these agents, experience with antidotes is limited. No agent is superior to the other and dosing for each agent is per product information. When prescribing these agents, we prefer that they be administered by clinicians knowledgeable in their use in accordance with study criteria that proved their efficacy. (See <a class="local">'Direct thrombin and factor Xa inhibitors'</a> below and  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a> and <a class="local">'Risk of bleeding'</a> below.)</p><p></p><p class="bulletIndent1">Importantly, these agents are <strong>not</strong> suitable for the treatment of hemodynamically unstable pulmonary embolism (PE), massive iliofemoral deep vein thrombosis (DVT; eg, phlegmasia cerulea dolens), or for those who are pregnant. While these agents are contraindicated in those with severe renal insufficiency, renally-adjusted dosing can be made in those with mild-to-moderate impairment. Similarly, many experts avoid them in those with chronic liver disease in whom the INR may be elevated. For those in whom monitoring compliance and agent reversal is important, avoidance may also be appropriate. (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Chronic kidney disease'</a>.)</p><p></p><p class="bulletIndent1">Issues concerning long-term safety, drug-drug interactions, and use of these agents in those with hepatic disease still need to be clarified in future trials.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Warfarin</strong> – <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> is our preferred anticoagulant for patients in whom factor Xa or direct thrombin inhibitors are not available and for patients with severe renal insufficiency  (<a class="graphic graphic_table graphicRef91199" href="/d/graphic/91199.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> requires multiple office visits for INR monitoring and has a higher bleeding risk when compared with DOACs; however, antidotes for warfarin-related bleeding are more readily available. Thus, it may also be preferred in those with a preference or requirement for a readily reversible antidote (eg, need for frequent interventions) and those in whom therapeutic anticoagulation needs to be monitored (eg, poor compliance). Dosing for warfarin is discussed below. (See <a class="local">'Warfarin'</a> below.)</p><p></p><p class="bulletIndent1">Although <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is not absolutely contraindicated in patients with known protein C or S deficiency who are at increased risk of warfarin-induced skin necrosis, patients can be treated with warfarin overlapped with heparin, if DOACs cannot be administered. (See  <a class="medical medical_review" href="/d/html/1354.html" rel="external">"Protein C deficiency", section on 'Warfarin-induced skin necrosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low molecular weight (LMW) heparin</strong> – Subcutaneous LMW heparin is an acceptable alternative for nonpregnant patients in whom oral medications are not feasible (eg, malabsorption). It is the preferred therapy for DVT during pregnancy and for patients with active malignancy. Some experts also prefer this agent in those with liver disease since the elevated INR in this population may not reflect the effect of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>. Laboratory monitoring is not required. No agent is superior to the other and dosing for each agent is per product information. They are contraindicated in patients with severe renal dysfunction (creatinine clearance &lt;30 mL/minute); dosing adjustment for mild renal insufficiency are listed in the table  (<a class="graphic graphic_table graphicRef90258" href="/d/graphic/90258.html" rel="external">table 3</a>). (See <a class="local">'Low molecular weight heparin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fondaparinux</strong> – <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">Fondaparinux</a> is a subcutaneous factor Xa inhibitor. Like LMW heparin, monitoring is not necessary in routine practice and it is contraindicated in patients with severe renal dysfunction. It is an alternative to LMW heparin when LMW heparin cannot be administered because of a history or diagnosis of heparin-induced thrombocytopenia [HIT]. (See <a class="local">'Fondaparinux'</a> below and  <a class="medical medical_review" href="/d/html/1319.html" rel="external">"Fondaparinux: Dosing and adverse effects"</a>.)</p><p></p><p class="headingAnchor" id="H1693420585"><span class="h2">Special populations</span><span class="headingEndMark"> — </span>Special populations of patients with acute VTE requiring specific consideration include those listed below  (<a class="graphic graphic_table graphicRef107541" href="/d/graphic/107541.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H4250978671"><span class="h3">Malignancy</span><span class="headingEndMark"> — </span>The treatment of VTE and duration of anticoagulation in patients with malignancy is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a>.)</p><p class="headingAnchor" id="H575706312"><span class="h3">Pregnancy</span><span class="headingEndMark"> — </span>LMW heparin is the preferred agent for long-term anticoagulation in pregnant women with acute VTE  (<a class="graphic graphic_table graphicRef140440" href="/d/graphic/140440.html" rel="external">table 4</a>). The treatment of VTE, duration of therapy, and use of anticoagulants in pregnancy are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1350.html" rel="external">"Venous thromboembolism in pregnancy and postpartum: Treatment"</a> and  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p class="headingAnchor" id="H4279579412"><span class="h3">Heparin-induced thrombocytopenia</span><span class="headingEndMark"> — </span>For patients with VTE and a diagnosis of heparin-induced thrombocytopenia (HIT), anticoagulation with heparin, including UFH and LMW heparin, is <strong>contraindicated</strong>. Anticoagulation with a nonheparin anticoagulant should be administered. The management of patients with HIT is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a> and  <a class="medical medical_review" href="/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia"</a>.)</p><p class="headingAnchor" id="H1442417439"><span class="h3">Antiphospholipid antibody syndrome</span><span class="headingEndMark"> — </span>For patients with antiphospholipid syndrome, extended anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is recommended, the details of which are discussed separately. (See  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a>.)</p><p class="headingAnchor" id="H1692346705"><span class="h2">Isolated distal deep vein thrombosis</span><span class="headingEndMark"> — </span>One retrospective study reported similar rates of recurrence and bleeding among patients treated with anticoagulation for isolated distal DVT compared with those who had proximal DVT [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H28215420"><span class="h1">AGENTS FOR LONG-TERM ANTICOAGULATION</span><span class="headingEndMark"> — </span>Full anticoagulation should be ensured during the transition from initial to long-term (maintenance) therapy. Interruptions should be minimized during the first three months of anticoagulation because this is the period that has the highest risk of recurrent thrombosis. The optimal transition strategy varies with the long-term anticoagulant chosen. In some patients, the agent chosen for long-term use is the same agent that was selected for initial anticoagulation (eg, low molecular weight [LMW] heparin, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, and <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>), but in others, the initial agent and the selected long-term agent belong to different classes, such that transitioning from one agent to another is necessary (eg, heparin to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, heparin to <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a> or <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>). Transition strategy, dosing, and efficacy of specific anticoagulants are discussed in the sections below.</p><p class="headingAnchor" id="H276144205"><span class="h2">Direct thrombin and factor Xa inhibitors</span><span class="headingEndMark"> — </span>For patients with acute VTE, factor Xa inhibitors (<a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>) and direct thrombin inhibitors (<a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>) are first-choice oral anticoagulants for long-term anticoagulation in most nonpregnant patients who do not have severe renal insufficiency or active cancer  (<a class="graphic graphic_table graphicRef91199" href="/d/graphic/91199.html" rel="external">table 2</a>). (See <a class="local">'Selection of agent'</a> above.)</p><p>They are fixed-dose oral agents that, unlike <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, do not require routine laboratory monitoring and dose adjustments. These agents reach their peak efficacy within one to four hours after ingestion so that, unlike when transitioning to warfarin, a prolonged period of bridging therapy is not required when switching from initial treatment (eg, with <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> [UFH] or LMW heparin) to these agents. In general, the direct oral anticoagulant (DOAC) is started when continuous infusion of UFH is stopped or when (or slightly before) the next dose of therapeutic LMW heparin would have been due. Specific recommendations for transitioning from parenteral anticoagulation to each DOAC are provided in the Lexicomp drug monographs included in UpToDate for each DOAC. Transitioning during anticoagulant therapy is discussed separately. (See <a class="local">'Switching anticoagulants during therapy'</a> below.)</p><p>Details regarding treatment of bleeding on these agents and reversibility agents are discussed separately. (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a>.)</p><p class="headingAnchor" id="H1254548103"><span class="h3">Dosing</span><span class="headingEndMark"> — </span>When an oral factor Xa or direct thrombin inhibitor is chosen for long-term anticoagulation, we prefer that they be initiated in accordance with study criteria that demonstrated their efficacy [<a href="#rid10">10-15</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">Rivaroxaban</a> and <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> can be administered as monotherapy (ie, no overlap or prior treatment with parenteral anticoagulant [eg, LMW heparin] is necessary), but short courses of parenteral anticoagulant should be administered when there is a delay in obtaining these agents (eg, not available in local pharmacy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">Edoxaban</a> and <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> are preferably administered following a five-day course of parenteral anticoagulation.</p><p></p><p>None of the factor Xa or direct thrombin inhibitors require bridging or need to be overlapped, unlike <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, since the anticoagulant effect is assured within one to four hours after ingestion. Thus, when switching patients from LMW heparin, factor Xa or direct thrombin inhibitors are generally given within 6 to 12 hours following the last dose of a twice daily regimen of subcutaneous LMW heparin or within 12 to 24 hours for once daily regimens. Factor Xa and direct thrombin inhibitors can be ingested immediately upon the discontinuation of intravenous (IV) UFH infusion. Transition regimens are discussed in detail below. (See <a class="local">'Switching anticoagulants during therapy'</a> below.)</p><p>Typical initial doses in those with normal renal function are:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">Rivaroxaban</a> 15 mg by mouth twice daily for 21 days followed by 20 mg once daily</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">Apixaban</a> 10 mg twice daily for seven days followed by 5 mg twice daily (2.5 mg twice daily for extended treatment beyond six months)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">Edoxaban</a> 60 mg once daily</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">Dabigatran</a> 150 mg twice daily</p><p></p><p>Dosing in renal insufficiency is discussed separately. (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Chronic kidney disease'</a>.)</p><p>There is a boxed warning in the US label not to use <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a> for patients with atrial fibrillation who have a creatinine clearance (CrCl) &gt;95 mL/minute as estimated by the Cockcroft-Gault equation due to a higher rate of ischemic stroke when compared to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>. Whether a similar increased risk of recurrent VTE occurs in this population is unknown. However, until these data are available in patients with VTE, we prefer to avoid the use of edoxaban in patients with a CrCl &gt;95 mL/minute. When calculating CrCl, we suggest a more precise assessment if edoxaban is to be used (<a class="calc calc_professional" href="/d/html/13496.html" rel="external">calculator 1</a>). (See  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants", section on 'Dosing'</a>.)</p><p>Other concerns regarding these agents include their distribution and efficacy in the obese population, which is understudied [<a href="#rid16">16</a>]. While randomized trials report efficacy for standard dosing in those with a body weight (BW) ≤100 kg or body mass index (BMI) ≤30 kg per m<sup>2</sup>, limited data from the International Society on Thrombosis and Hemostasis suggest similar efficacy in those with a BW &gt;120 kg or BMI ≥40 kg per m<sup>2</sup> [<a href="#rid16">16</a>], and small retrospective analyses suggested similar efficacy when compared with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid17">17,18</a>].The efficacy is unclear in those with a BW between 101 to 119 kg or BMI 31 to 39 kg per m<sup>2</sup>. The ISTH suggest using <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> and <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> at standard dosing rather than other DOACs in those with BW &gt;120 kg or BMI ≥40 kg per m<sup>2</sup>.</p><p>Caution is advised when inducers or inhibitors of P-glycoprotein and cytochrome P450 are prescribed. Drug interactions with other agents are discussed in the table  (<a class="graphic graphic_table graphicRef112756" href="/d/graphic/112756.html" rel="external">table 5</a>).</p><p>Manufacturer recommendations on compatibility of DOACs with feeding tube administration vary for each agent. For example, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> may be crushed and suspended in water whereas <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> capsules should not be opened due to substantial increase in drug exposure. These and other pharmacokinetic details are provided in the Lexicomp drug monographs included within UpToDate, "administration" field.</p><p class="headingAnchor" id="H2521579920"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Large randomized trials and meta-analyses have reported the safety and efficacy of these agents for the treatment and prevention of recurrent VTE (deep vein thrombosis [DVT] and/or pulmonary embolism [PE]) [<a href="#rid10">10-15,19-21</a>]. Most of these trials were performed in stable patients and were designed as noninferiority trials that compare the newer agent with standard anticoagulation (ie, heparin followed by <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) and showed comparable safety and efficacy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rivaroxaban</strong> – <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">Rivaroxaban</a> is an oral factor Xa inhibitor that demonstrated similar efficacy to conventional therapy (heparin followed by <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) for the treatment of acute VTE in a large, prospective, randomized controlled trial. For most patients receiving rivaroxaban, no parenteral anticoagulation was administered, and rivaroxaban was the initial anticoagulant used. EINSTEIN-DVT and EINSTEIN-PE were open-label randomized trials that enrolled a total of 8281 patients with acute DVT or PE and demonstrated the noninferiority of rivaroxaban (15 mg twice daily for 21 days followed by 20 mg once daily) to conventional therapy (<a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> followed by warfarin) for a treatment period of 3, 6, or 12 months [<a href="#rid10">10,11</a>]. Compared with conventional therapy, rivaroxaban resulted in similar rates of recurrent DVT (2.1 versus 3 percent), PE (2.1 versus 1.8 percent), and total bleeding events (8.1 versus 8.1 [EINSTEIN-DVT]; 10.3 versus 11.4 percent [EINSTEIN-PE]). In a post-hoc analysis of EINSTEIN-DVT and interrogation of a national registry, rivaroxaban was associated with a nonsignificant reduction in the rate of post-thrombotic syndrome [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Graduated compression stockings'</a> and  <a class="medical medical_review" href="/d/html/8200.html" rel="external">"Post-thrombotic (postphlebitic) syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Apixaban</strong> – <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">Apixaban</a> is an oral factor Xa inhibitor. AMPLIFY was a prospective, randomized, double-blind trial that compared apixaban (10 mg twice daily for seven days for initial anticoagulation followed by 5 mg twice daily for six months) with conventional anticoagulation (subcutaneous <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> for five days followed by <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> for six months) in 5395 patients for the treatment of acute VTE (DVT and/or PE) [<a href="#rid12">12</a>]. There was no difference in the rates of recurrent symptomatic VTE or VTE-related death (2.3 versus 2.7 percent) between the groups, and fewer bleeding events were reported in the apixaban group (4.3 versus 9.7 percent). Subgroup analysis suggested that the efficacy of apixaban for the prevention of VTE or VTE-related deaths occurred in all patient groups (eg, DVT, PE, unprovoked VTE, extensive PE). Large-scale cohort analyses suggest similar efficacy in practice [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Edoxaban</strong> – <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">Edoxaban</a> is an oral factor Xa inhibitor that has been shown to have a similar efficacy and superior safety profile when compared with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> for the treatment of acute VTE. In one trial, 4921 patients with acute VTE (DVT and/or PE) were randomized to receive 3 to 12 months of edoxaban or warfarin following initial therapy for five days with unfractionated or LMW heparin [<a href="#rid13">13</a>]. Edoxaban was administered orally at 60 mg once daily. A lower dose (30 mg once daily) was used for patients with a CrCl of 30 to 50 mL per minute or low body weight ≤60 kg. Compared with warfarin, edoxaban had a similar rate of recurrent symptomatic VTE or VTE-related death (3.2 versus 3.5 percent) and fewer bleeding events (8.5 versus 10.3 percent). A post-hoc analysis of the patients on low dose edoxaban showed similar results [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">Of potential clinical interest was the superior efficacy in the prespecified subgroup of patients with PE that had right ventricular (RV) dysfunction as assessed by elevated brain natriuretic peptide (BNP) or increased RV dimensions on computed tomography (CT). However BNP is a nonspecific biomarker of RV dysfunction, and echocardiography is a more accurate test than CT for the assessment of RV dysfunction. Further study of this agent in this population of patients with severe PE and RV dysfunction by echocardiogram is warranted to validate these findings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dabigatran</strong> – <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">Dabigatran</a> is an oral direct thrombin inhibitor. A large, randomized controlled trial suggested that dabigatran has similar efficacy to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> for the prevention of recurrent VTE. However, concerns have been raised about its efficacy and risk of thrombosis given the broad inferiority margin set in one of the trials (RE-COVER). In a randomized, double-blind trial (RE-COVER I), 2539 patients with acute VTE were treated for six months with either dabigatran (150 mg by mouth twice per day) or warfarin, each after seven days of initial parenteral anticoagulation [<a href="#rid14">14</a>]. Compared with warfarin, dabigatran had a similar incidence of recurrent VTE or VTE-related deaths (2.4 versus 2.1 percent), VTE-related deaths (0.1 versus 0.2 percent), major bleeding events (1.6 versus 1.9 percent), and any bleeding event (16.1 versus 21.9 percent). These results suggest that the efficacy and safety profile of dabigatran is similar to that of warfarin for the treatment of acute VTE. Similar results were reported in an identically designed trial of 2589 patients with acute DVT (RECOVER II) [<a href="#rid15">15</a>] and in a pooled analysis of RE-COVER I and II [<a href="#rid26">26</a>]. In a post hoc analysis of these trials, the efficacy appears to be maintained in patients with thrombophilia and antiphospholipid syndrome [<a href="#rid27">27</a>].</p><p></p><p>Meta-analyses support individual findings. As an example, one meta-analysis of 64 studies that compared DOACs with standard anticoagulation, usually <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, reported no difference in VTE recurrence rate (risk reduction [RR] 0.93, 95% CI 0.53-1.63 [oral direct thrombin inhibitors]; RR 0.85, 95% CI 0.63-1.13 [factor Xa inhibitors]) and possibly lower bleeding rates with DOACS (RR 0.51, 95% CI 0.15-1.67 [oral direct thrombin inhibitors]; RR 0.91, 95% CI 0.56-1.48 [factor Xa inhibitors]) [<a href="#rid4">4</a>].</p><p>No randomized trials have directly compared individual DOACs with each other. However, retrospective data suggest that <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> may have lower rates of recurrent VTE and bleeding than <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> [<a href="#rid28">28-30</a>]. As an example, in data derived from an insurance database, among 37,000 new users of apixaban and rivaroxaban, apixaban was associated with a lower rate of recurrent VTE (hazard ratio [HR] 0.77, 95% CI 0.69-0.87) and bleeding (HR 0.60, CI 0.53-0.69) [<a href="#rid30">30</a>]. Reasons for this difference are unknown but could be due to differences in the population characteristics or differences in the pharmacokinetics (eg, less fluctuations in drug concentration with apixaban [<a href="#rid31">31</a>]).</p><p>Retrospective data suggest that efficacy of DOACS compared with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is maintained in older patients (eg, &gt;80 years) [<a href="#rid32">32</a>].</p><p>The bleeding risk of these agents is discussed in greater detail below. (See <a class="local">'Factor Xa and direct thrombin inhibitors'</a> below.)</p><p class="headingAnchor" id="H105731110"><span class="h2">Warfarin</span></p><p class="headingAnchor" id="H105731226"><span class="h3">Dosing</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> is the preferred agent for nonpregnant patients in whom factor Xa or direct thrombin inhibitors are not available and for patients with severe renal dysfunction. It may also be preferred in those in whom therapeutic anticoagulation needs to be closely monitored  (<a class="graphic graphic_table graphicRef91199" href="/d/graphic/91199.html" rel="external">table 2</a>). (See <a class="local">'Selection of agent'</a> above.)</p><p>When <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is chosen as the agent for long-term anticoagulation, it is generally started on the same day with LMW heparin or UFH (day 1) at a typical initiating dose of 5 mg/day for the first two days (range 2 to 10 mg/day)  (<a class="graphic graphic_table graphicRef71791" href="/d/graphic/71791.html" rel="external">table 6</a>) [<a href="#rid33">33,34</a>]. Dosing is then adjusted until the INR is within the therapeutic range (2 to 3; target 2.5) for two consecutive days. Initial doses at the lower range (2 to 5 mg/day) may be considered in those assessed at high bleeding risk (eg, older adults), and doses in the higher range (5 to 10 mg/day) may be selected in healthy individuals who are at low risk for bleeding. (See  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Initial dosing'</a> and  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation", section on 'Anticoagulant agents'</a>.)</p><p>The premature cessation of heparin before <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> has taken its full effect (ie, therapeutic INR for two days) may result in inadequate protection against recurrent thrombosis. This overlap is required because it takes a number of days for all of the vitamin K-dependent factors to become depleted (factors II, VII, IX, and X). During the first few days of warfarin therapy, prolongation of the prothrombin time (PT; as reflected by the INR) mainly reflects the depression of factor VII, which has a short half-life (hours)  (<a class="graphic graphic_figure graphicRef50940" href="/d/graphic/50940.html" rel="external">figure 1</a>). Importantly, this does not represent adequate anticoagulation because additional vitamin K-dependent factors are insufficiently reduced (takes approximately five days with adequate dosing). In addition, reduction of protein C and S occurs shortly after warfarin therapy and potentially renders a procoagulant state. Together, these factors increase the likelihood of recurrent thrombosis should patients not be fully anticoagulated with parenteral heparin. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis"</a> and  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Warfarin administration'</a>.)</p><p class="headingAnchor" id="H105731232"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Data that support the efficacy of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> as an anticoagulant in patients with VTE are derived from older studies that compared warfarin with no anticoagulation or low-dose subcutaneous heparin and from randomized trials and meta-analyses of variable durations of therapeutic anticoagulation [<a href="#rid35">35-45</a>]. In the seminal trial, performed in 1960, that compared warfarin with observation in patients with acute DVT, warfarin resulted in a dramatic reduction in recurrence (0 versus 26 percent), which translated into a mortality benefit (26 versus 0 percent) [<a href="#rid45">45</a>]. Since then, most other trials have compared various durations of warfarin therapy to provide an estimate of the risk of recurrence [<a href="#rid36">36,44</a>]. Cumulatively, these data all support low rates of recurrent VTE and death in patients treated with warfarin therapy for proximal DVT, with the greatest benefit occurring within the first few days or weeks of the initial event. As an example, one 2010 meta-analysis of 13 prospective cohort studies and 56 randomized clinical trials reported rates of recurrent VTE and fatal VTE during the first three months of warfarin therapy as 3.4 and 0.4 percent, respectively [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H105731116"><span class="h2">Low molecular weight heparin</span></p><p class="headingAnchor" id="H105732393"><span class="h3">Dosing</span><span class="headingEndMark"> — </span>Low molecular weight (LMW) heparin is the preferred agent for those in whom treatment with one of the oral agents is not feasible (eg, patients with poor or no oral intake). (See <a class="local">'Selection of agent'</a> above.)</p><p>When subcutaneous LMW heparin is chosen for long-term anticoagulation and UFH is the initial anticoagulant being used, LMW heparin can be administered and the UFH infusion immediately discontinued.</p><p>The initiating dose of LMW heparin is individualized according to each product. Dosing is typically weight-based and continued at the same dose used for initial anticoagulation. Dosing for patients with renal insufficiency is listed in the table  (<a class="graphic graphic_table graphicRef90258" href="/d/graphic/90258.html" rel="external">table 3</a>). LMW heparin is contraindicated in patients with severe renal insufficiency (CrCl &lt;30 mL/minute). (See  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation", section on 'Low molecular weight heparin'</a> and  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'LMW heparin'</a>.)</p><p class="headingAnchor" id="H105732399"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Several randomized trials and meta-analyses have shown that LMW heparin is at least as effective as <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> in the prevention of recurrent VTE (DVT and/or PE) with a similar rate of major bleeding and mortality [<a href="#rid46">46-48</a>]. However, many of the trials have potential bias for the assessment of recurrent VTE and imprecision in the assessment of major bleeding and mortality, which limits the analysis.</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A 2017 meta-analysis of 16 trials of patients with VTE (total 3299 patients) compared LMW heparin with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid47">47</a>]. LMW heparin was as effective as warfarin in preventing symptomatic VTE (odds ratio [OR] 0.83; 95% CI 0.6-1.15) and was associated with a nonsignificant trend in lower bleeding rates (OR 0.62, 95% CI 0.36-1.07). No difference in mortality was observed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another 2012 meta-analysis of eight trials that restricted analysis to only those trials that used ≥50 percent of the full therapeutic dose of LMW heparin, reported a reduction in recurrent VTE compared to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> (RR 0.62, 95% CI 0.46-0.84) with a similar rate of major bleeding and mortality [<a href="#rid46">46</a>].</p><p></p><p>Randomized trials have also suggested that, compared with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, long-term anticoagulation with LMW heparin lowers the frequency of post-thrombotic syndrome (PTS), a treatable, late complication of acute DVT [<a href="#rid49">49-51</a>]. One 2011 systematic review of nine trials of patients with DVT reported that, compared with other agents (mostly warfarin), LMW heparin was associated with a reduction in the rate of PTS signs and symptoms (OR 0.77), recanalization of thrombosed veins (RR 0.66), and venous ulceration (RR 0.13) [<a href="#rid51">51</a>]. However, the major indication for anticoagulation is the prevention of recurrence rather than the prevention of PTS such that the latter does not practically influence agent selection. (See  <a class="medical medical_review" href="/d/html/8200.html" rel="external">"Post-thrombotic (postphlebitic) syndrome"</a> and  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Graduated compression stockings'</a>.)</p><p>Long-term anticoagulation with LMW heparin has never been directly compared with factor Xa or direct thrombin inhibitors. (See <a class="local">'Direct thrombin and factor Xa inhibitors'</a> above.)</p><p class="headingAnchor" id="H105731129"><span class="h2">Fondaparinux</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">Fondaparinux</a>, a pentasaccharide, is an alternative to LMW heparin when the latter is contraindicated in patients with heparin-induced thrombocytopenia (HIT). (See <a class="local">'Selection of agent'</a> above.)</p><p>When transitioning from initial anticoagulation with UFH, subcutaneous <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> can be administered and the UFH infusion immediately discontinued. Fondaparinux is typically dosed according to the usual initiating dose. Subcutaneous fondaparinux is contraindicated in patients with severe renal insufficiency (CrCl &lt;30 mL/minute) and may accumulate in patients with moderate renal insufficiency (CrCl 30 to 50 mL/minute). Information on dosing is provided separately. (See  <a class="medical medical_review" href="/d/html/1319.html" rel="external">"Fondaparinux: Dosing and adverse effects"</a>.)</p><p>Although <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> is less well studied than LMW heparin as a long-term anticoagulant, fondaparinux appears to have a similar efficacy and safety profile to the LMW heparin, <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> when used as an initial anticoagulant. A meta-analysis of pentasaccharides that included fondaparinux also reported similar efficacy when fondaparinux was given in combination with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid52">52</a>].</p><p>Detailed discussion of <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> dosing and adverse effects are provided separately. (See  <a class="medical medical_review" href="/d/html/1319.html" rel="external">"Fondaparinux: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H105733091"><span class="h2">Unfractionated heparin (subcutaneous)</span><span class="headingEndMark"> — </span>Anecdotally, subcutaneous UFH may be a useful alternative in patients who are unable or unwilling to take <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> or LMW heparin (eg, patients with renal insufficiency unable to take an oral medication). In one randomized open-label study of 697 patients with acute DVT, there were no differences in efficacy or bleeding rates between fixed-dose subcutaneous UFH (333 units/kg initially, followed by 250 units/kg twice daily) and low molecular weight heparin (<a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a>/<a class="drug drug_general" data-topicid="9319" href="/d/drug information/9319.html" rel="external">dalteparin</a>) when used as initial anticoagulants and overlapped with warfarin [<a href="#rid53">53</a>]. However, long-term anticoagulation with subcutaneous UFH has been inadequately studied and has never been compared with factor Xa or direct thrombin inhibitors.</p><p class="headingAnchor" id="H2329861"><span class="h1">DURATION OF TREATMENT</span></p><p class="headingAnchor" id="H1855298662"><span class="h2">Duration</span><span class="headingEndMark"> — </span>It is critical that the duration of anticoagulation therapy be individualized according to the presence or absence of provoking events and risk factors, risk for recurrence and bleeding  (<a class="graphic graphic_table graphicRef107542" href="/d/graphic/107542.html" rel="external">table 7</a> and <a class="graphic graphic_table graphicRef107543" href="/d/graphic/107543.html" rel="external">table 8</a>), as well as to the individual patient preferences and values  (<a class="graphic graphic_algorithm graphicRef131964" href="/d/graphic/131964.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef131963" href="/d/graphic/131963.html" rel="external">algorithm 2</a>). Our approach is consistent with guidelines set out by the American College of Chest Physicians, the International Society of Thrombosis and Hemostasis, and the International Consensus Statement on the Prevention and Treatment of Venous Thromboembolism [<a href="#rid4">4,35,46,54</a>]. Importantly, the data in this section do <strong>not</strong> apply to patients with cancer, pregnant women, or patients in whom indefinite anticoagulation should be considered; anticoagulation in these populations is discussed separately. (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a> and  <a class="medical medical_review" href="/d/html/1350.html" rel="external">"Venous thromboembolism in pregnancy and postpartum: Treatment"</a> and  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p>In general, the following applies:</p><p class="bulletIndent1"><span class="glyph">●</span>Most patients with a first episode of VTE (provoked or unprovoked) should receive anticoagulation for a minimum of <strong>three months</strong>. In select populations, anticoagulation is extended to <strong>6 or 12</strong> months (eg, phlegmasia cerulea dolens, a persisting but reversible risk factor, hemodynamically significant PE), although the benefits of this are unproven.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Selecting patients for a duration of anticoagulation beyond three months including patients who may be candidates for <strong>indefinite</strong> anticoagulation and the factors involved in this decision  (<a class="graphic graphic_table graphicRef131266" href="/d/graphic/131266.html" rel="external">table 9</a>) are discussed separately. (See  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a> and  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy", section on 'Duration of anticoagulation'</a>.)</p><p></p><p class="headingAnchor" id="H90833414"><span class="h2">Supporting evidence</span><span class="headingEndMark"> — </span>Evidence supporting anticoagulation for a minimum of three months is derived from randomized trials and meta-analyses in patients with acute VTE that comprised a significant proportion of patients with an unprovoked event (also known as idiopathic or spontaneous VTE). The evidence is weaker for patients with distal deep vein thrombosis (DVT), particularly episodes that are provoked by a reversible or transient factor (eg, orthopedic surgery) and for patients with asymptomatic, incidental, or small subsegmental PE.</p><p>Cumulatively, evidence from randomized trials and meta-analyses suggests that:</p><p class="bulletIndent1"><span class="glyph">●</span>Without adequate anticoagulation (eg, no anticoagulation, prophylactic doses of anticoagulants) the risk of recurrent venous VTE (DVT and PE) is highest during the first three months following the initial event [<a href="#rid35">35-43,46</a>]. (See  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Shortening the course of anticoagulation from three or six months to four or six weeks is associated with an increased risk for recurrent VTE, even in patients with distal DVT [<a href="#rid37">37,41,42,55</a>].</p><p></p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A 2012 meta-analysis of five randomized trials reported that, compared with three months of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy, four to six weeks resulted in an increase in the absolute risk of recurrent VTE (53 more episodes of VTE per 1000), compared with only a small decrease in the risk of major bleeding (5 fewer major bleeding episodes per 1000) [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another 2011 meta-analysis of seven randomized trials of patients without cancer who had a first episode of VTE, recurrence was higher if anticoagulation (usually <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) was stopped at four or six weeks, compared with three months or later (hazard ratio 1.52, 95% CI 1.14-2.02) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another meta-analysis of randomized trials and cohort studies of patients with isolated distal DVT, a lower rate of recurrent VTE was reported in patients anticoagulated for more than six weeks compared with patients treated with a six week course of anticoagulant therapy [<a href="#rid56">56</a>]. A subsequent randomized trial in the same population has shown the same results [<a href="#rid55">55</a>].</p><p></p><p>However, the majority of patients in these trials had <strong>proximal</strong> DVT and/or PE (provoked and unprovoked). Although patients with <strong>distal</strong> DVT have a low risk of recurrence (approximately 1 percent per year), it is unknown whether shorter courses (four to six weeks) are adequate in this population [<a href="#rid46">46</a>]. Nonetheless, based upon data extrapolated from the population of patients with proximal DVT, we prefer that patients with distal DVT be anticoagulated for three months [<a href="#rid35">35,46</a>].</p><p>Many experts extend anticoagulation for <strong>finite</strong> periods (eg, 6 to 12 months) in some patients, including those with extensive or life-threatening episodes of provoked VTE or patients with provoked VTE and persistent reversible risk factors (eg, prolonged immobility, continued estrogen use), provided the risk of bleeding is low [<a href="#rid35">35,42,46</a>]. This practice is in contrast to data from randomized trials and meta-analyses that, in general, report no benefit to cessation of long-term therapy after a more prolonged, finite period beyond three months (eg, 6 or 12 months) in patients at average risk:</p><p class="bulletIndent1"><span class="glyph">●</span>One 2012 meta-analysis of five trials of patients with acute VTE reported that, compared with three months of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy, 6 or 12 months of therapy did not convincingly lower the risk of recurrence (RR 0.89, 95% CI 0.69-1.14), but did increase the risk of bleeding by approximately 2.5-fold [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2011 meta-analysis of seven randomized trials VTE recurrence was similar if treatment was stopped at three months, compared with six months or later (RR 1.19, 0.86-1.65) [<a href="#rid42">42</a>].</p><p></p><p>The rationale for altering practice in these "higher risk" patients is that many trials excluded such patients. This disparity between clinical practice and published trials may be due to the exclusion from trials of patients that may theoretically benefit from longer courses of anticoagulation (eg, extensive or life-threatening VTE). In addition, the data suggest that the risk of recurrence does continue to decline between three and six months on anticoagulant therapy. For these reasons, guidelines and many experts use a three- to six-month range for an optimal duration of therapy for patients with provoked VTE who are at low risk of bleeding and in whom the risk of recurrence is still assessed by the clinician as high [<a href="#rid35">35</a>]. By the same token, completing therapy at three months is also appropriate for patients with a moderate to high bleeding risk.</p><p>Some clinicians advocate flexible durations of therapy based upon the identification of residual clot. For example, one study (AESOPUS) used ultrasound for the detection of residual thrombosis after three months of anticoagulation to determine whether therapy should be extended in some patients to six months [<a href="#rid57">57</a>]. Compared with a fixed duration of three months, flexible duration of therapy that was ultrasound directed resulted in a reduction in recurrent VTE (12 versus 17 percent) [<a href="#rid57">57</a>]. Although this practice is not validated in a large randomized trial setting, it may be considered on a case-by-case basis. (See  <a class="medical medical_review" href="/d/html/1351.html" rel="external">"Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity", section on 'Suspected recurrent DVT'</a> and  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'First VTE with persistent nonmalignant risk factor'</a>.)</p><p>Limited evidence suggests a similar approach for patients with coronavirus disease 2019 (COVID-19). These data are discussed separately. (See  <a class="medical medical_review" href="/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability", section on 'Choice of anticoagulant and dosing'</a>.)</p><p class="headingAnchor" id="H105730846"><span class="h1">SWITCHING ANTICOAGULANTS DURING THERAPY</span><span class="headingEndMark"> — </span>Interruptions should be limited especially during the first three months of anticoagulation. However, anticoagulants may need to be changed for medical reasons as well as for altered patient preferences. Reasons for switching agents include:</p><p class="bulletIndent1"><span class="glyph">●</span>The development of renal insufficiency (prolongs the half-life of low molecular weight [LMW] heparin, <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a>, and factor Xa and direct thrombin inhibitors [ie, direct oral anticoagulants (DOACs)])</p><p class="bulletIndent1"><span class="glyph">●</span>Perceived burdens of laboratory testing for <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a></p><p class="bulletIndent1"><span class="glyph">●</span>Poor compliance or difficulty with international normalized ratio (INR) testing</p><p class="bulletIndent1"><span class="glyph">●</span>Resolution of active cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Pain or inflammation at injection sites</p><p class="bulletIndent1"><span class="glyph">●</span>Cost</p><p class="bulletIndent1"><span class="glyph">●</span>Need for repeated invasive procedures</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrence despite therapeutic anticoagulation</p><p></p><p>Clinicians should alert their patients that switching anticoagulants is associated with an unquantifiable increased risk of both bleeding and recurrence. these risks are less well studied in patients transitioning to and from factor Xa and direct thrombin inhibitors [<a href="#rid58">58</a>]. When switching to or from these agents, we prefer to use protocols that are similar to that performed in trials that studied these agents in patients with atrial fibrillation and VTE.</p><p>In general, the following applies:</p><p class="bulletIndent1"><span class="glyph">●</span>Transitioning from LMW heparin:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>To <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> should be the same as for initial anticoagulation. Warfarin and heparin are simultaneously administered for four to five days until the INR is therapeutic for a minimum of 24 hours or two consecutive days. (See <a class="local">'Agents for long-term anticoagulation'</a> above and  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Warfarin administration'</a> and  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation", section on 'Duration of therapy for heparin'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>To factor Xa or direct thrombin inhibitors (DOACs) is generally done by administering the oral agent within zero to two hours before the next scheduled dose of LMW heparin is due. Specific recommendations for transitioning from parenteral anticoagulation to each DOAC are provided in the Lexicomp drug monographs included in UpToDate for each DOAC. (See <a class="local">'Direct thrombin and factor Xa inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transitioning from <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>To <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is discussed separately. (See <a class="local">'Warfarin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>To a DOAC is usually done by starting the DOAC when a continuous infusion of UFH is stopped as DOACs have a rapid onset of action, with a peak anticoagulant effect occurring two to three hours after intake. Specific recommendations for transitioning from parenteral anticoagulation to each DOAC are provided in the Lexicomp drug monographs included in UpToDate for each DOAC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Direction on switching oral agents is provided separately  (<a class="graphic graphic_table graphicRef120639" href="/d/graphic/120639.html" rel="external">table 10</a>). (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Transitioning between anticoagulants'</a>.)</p><p></p><p>Perioperative management of anticoagulation is discussed separately. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p class="headingAnchor" id="H28215432"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>All patients on anticoagulation should be monitored clinically for therapeutic efficacy (recurrence), bleeding, as well as the development of conditions that affect the half-life of the medications used (eg, renal failure, pregnancy, weight gain/loss) and adverse effects of the medications (eg, skin necrosis, thrombocytopenia, osteoporosis). Laboratory monitoring varies with the long-term anticoagulant used:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factor Xa and direct thrombin inhibitors</strong> – These agents do not require routine laboratory monitoring because they are administered in fixed-dose regimens without dose adjustments and laboratory parameters have not been correlated with clinical endpoints. They should be administered by physicians knowledgeable in their use and in accordance with study criteria that proved their efficacy. Patients should be carefully monitored clinically for bleeding and for renal failure. Monitoring therapeutic efficacy is difficult but is performed on rare occasions, for example in patients at the extremes of body weight (ie, &lt;50 kg, &gt;130 kg). In addition, a practice tool aimed at monitoring patients for the complications of these agents is published but not routinely used [<a href="#rid59">59</a>]. Further details regarding monitoring patients on these agents are discussed separately. (See <a class="local">'Direct thrombin and factor Xa inhibitors'</a> above and  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Warfarin</strong> – The most common laboratory test used to monitor <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is the prothrombin time (PT) ratio, usually expressed as the international normalized ratio (INR). The goal INR is 2 to 3 (target 2.5) [<a href="#rid34">34,60</a>]. Once the anticoagulant effect and the patient's warfarin dose requirements are stable, the INR should be monitored usually every three to four weeks throughout the course of warfarin therapy for VTE. More frequent monitoring is indicated if factors are present that may produce an unpredictable response to warfarin (eg, concomitant therapy with drugs that interact with warfarin); longer intervals (eg, up to 12 weeks) are feasible if the INR response is predictable [<a href="#rid34">34</a>]. Warfarin dosing must be individualized because factors including drug interactions, increased age, and specific genotypes alter the response to warfarin [<a href="#rid61">61</a>]. Genotype-guided dosing has no proven value over conventional monitoring in achieving this goal. Self-monitoring practices have proven efficacy in patients who demonstrate competency in self-management strategies. Further details regarding monitoring patients on warfarin are discussed separately. (See  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Warfarin administration'</a> and  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Self-monitoring and self-management'</a> and  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Prothrombin time (PT) and INR'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low molecular weight heparin and </strong><strong>fondaparinux</strong> – These agents do not require routine laboratory monitoring because laboratory parameters have not been correlated with clinical endpoints (recurrence and bleeding). However, patients should be monitored for the development of renal insufficiency, which can prolong their half-life. If there is any question as to the correct dose of low molecular weight (LMW) heparin (eg, for those with obesity or renal insufficiency), measuring antifactor Xa activity testing is sometimes used. <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">Fondaparinux</a> was not monitored in clinical studies and is therefore not monitored routinely in clinical practice. Measurement of fondaparinux drug levels may be appropriate in patients with major bleeding. Details regarding the therapeutic use of LMW heparin and fondaparinux and issues that may affect interinstitutional variability among tests used to monitor these agents are discussed separately. (See  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'LMW heparin'</a> and  <a class="medical medical_review" href="/d/html/1319.html" rel="external">"Fondaparinux: Dosing and adverse effects", section on 'Pharmacology'</a> and  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Monitoring heparins'</a>.)</p><p></p><p>There are no data to support the use of incentives or alerts to improve adherence to anticoagulants.</p><p class="headingAnchor" id="H545981134"><span class="h1">RISK OF BLEEDING</span><span class="headingEndMark"> — </span>All patients should be regularly assessed during anticoagulant therapy for bleeding risk  (<a class="graphic graphic_table graphicRef97160" href="/d/graphic/97160.html" rel="external">table 11</a>).</p><p class="headingAnchor" id="H2038463615"><span class="h2">Warfarin and low molecular weight heparin</span><span class="headingEndMark"> — </span>Evidence from randomized trials and meta-analyses suggest that the rate of bleeding on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and low molecular weight (LMW) heparin are generally low. As an example, one meta-analysis of 13 prospective cohort studies and 56 randomized clinical trials of patients treated for deep vein thrombosis (DVT) reported that during the first three months of anticoagulant therapy, rates of major bleeding and major fatal bleeding were 1.6 and 0.2 percent, respectively [<a href="#rid44">44</a>]. Rates of any bleeding events are usually higher, ranging from 5 to 15 percent, and the risk of bleeding is almost twice as high with the concomitant use of additional agents including nonsteroidal anti-inflammatory drugs (NSAIDs) or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (hazard ratio 2.37 and 1.50, respectively) [<a href="#rid62">62</a>]. However, reported rates may not accurately reflect those expected to occur in clinical practice, where the risk of bleeding varies significantly among individuals.</p><p class="headingAnchor" id="H3354601828"><span class="h2">Factor Xa and direct thrombin inhibitors</span><span class="headingEndMark"> — </span>For patients on factor Xa and direct thrombin inhibitors, data from randomized trials and meta-analyses have reported that rates of major bleeding events range from 0.6 to 1.6 percent and any bleeding events range from 4 to 16 percent.</p><p>Randomized trials and meta-analyses of patients with VTE report reduced rates of bleeding when these agents are compared with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid19">19-21,63-70</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Two 2023 meta-analyses of randomized trials, which included all of the major studies discussed above, reported that compared with conventional anticoagulation (heparin plus <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>), use of direct thrombin or factor Xa inhibitors resulted in reduced rates of bleeding (OR 0.63, 95% CI 0.45-0.89 for DVT; OR 0.71, 95% CI 0.36-1.41 for pulmonary embolism) [<a href="#rid20">20,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar results were reported in another meta-analysis that included additional trials of patients on these agents for atrial fibrillation [<a href="#rid68">68</a>]. A retrospective cohort study of patients hospitalized for intracranial hemorrhage also reported a 6 percent lower rate of in-hospital mortality for those on direct oral anticoagulants (DOACs) compared with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid71">71</a>]. Further details regarding risk of bleeding with DOACs are provided separately. (See  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants"</a>.)</p><p></p><p>Although bleeding rates may be lower with factor Xa and direct thrombin inhibitors, it is important to note that reported rates reflect that in study patients with a baseline low bleeding risk and may not represent that of the general population. As an example, in the months following the approval of <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> in other settings, the US Food and Drug Administration (FDA) received many reports of serious and fatal bleeding events associated with DOAC use, and reports of bleeding rates in older populations have been conflicting [<a href="#rid15">15,72-76</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>An independent analysis of bleeding events and bleeding-related fatalities from reports submitted to the FDA (from 2011 through 2012) showed that, compared with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, higher rates of bleeding events (4270 versus 827 events) and bleeding fatalities (638 versus 44 fatalities) were reported for <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While a 2013 mini-Sentinel analysis by the FDA suggested that <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> was being used in accordance with its labeled indications and bleeding rates did not appear to be higher than those associated with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, a subsequent 2014 FDA analysis reported an increased rate of gastrointestinal bleeding (GIB) among patients older than 65 years [<a href="#rid72">72,73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A pooled analysis of bleeding events with <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> in RECOVER I/II reported that a lower bleeding risk with dabigatran was only evident in younger patients and that, in those over the age of 85 years, the bleeding risk was lower with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Institute for Safe Medication Practices analyzed 1734 reports to the FDA from patients on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>, and <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> [<a href="#rid75">75</a>]. Dabigatran bleeds were five times more likely than warfarin to result in death (19 versus 4 percent; OR 5.2, 95% CI 3.4-8.0). The estimate of higher odds for a fatal outcome with dabigatran persisted after adjusting for age, sex, and report source.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postmarketing reports of bleeding, particularly for <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>, dampened initial enthusiasm for its use as anticoagulant therapy for VTE [<a href="#rid72">72,73,77</a>]. Increased risk of bleeding has also been reported in older patients (&gt;75 years) on dabigatran [<a href="#rid15">15,78,79</a>]. Dabigatran is renally excreted, and, although unproven, this risk may be due to the higher prevalence of renal insufficiency and longer half-life of dabigatran in older patients [<a href="#rid80">80</a>].</p><p></p><p>Preliminary reports on the safety of direct thrombin or factor Xa inhibitors, reflective of their use in general practice are limited.</p><p class="bulletIndent1"><span class="glyph">●</span>One 2016 retrospective analysis reported that 80 percent of patients with VTE were treated with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and that warfarin and direct thrombin or factor Xa inhibitors were associated with similar rates of recurrent VTE (1.2 versus 2.1 percent) and bleeding (0.5 percent) [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another retrospective review reported that over one-half of patients prescribed direct thrombin or factor Xa inhibitors (for atrial fibrillation and VTE) were underdosed, when compared with the manufacturer recommendations [<a href="#rid82">82</a>]. The rate of thromboembolic events was 11 percent (<a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>), 4 percent (<a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>), and 5 percent (<a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>); bleeding event rates were 18 percent (apixaban), 18 percent (rivaroxaban), and 24 percent (dabigatran). Some of the factors that may have influenced reduced-dose prescribing were previous history of bleeding and potential drug interactions.</p><p></p><p>Among the DOACs, rates of GIB are likely higher with <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> than other DOACS. One 2018 retrospective analysis of anticoagulant treatment (mostly given for atrial fibrillation) reported higher rates of upper GIB with rivaroxaban, while the lowest rates were in patients receiving <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> [<a href="#rid83">83,84</a>]; patients who were also receiving a proton pump inhibitor experienced reduced bleeding from all anticoagulants. A 2021 analysis that included over 3000 patients also reported that rivaroxaban had the highest rates of GIB when compared with apixaban (all GIB events: 3.2 versus 2.5 events per 100 person-years; major GIB events: 1.9 versus 1.4 events per 100 person-years) or <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> (all GIB events: 3.2 versus 1.9 events per 100 person-years; major GIB: 1.9 versus 1.4 events per 100 person-years) [<a href="#rid84">84</a>].</p><p>Retrospective data suggests that bleeding rates among octogenarians receiving a DOAC appear to be equivalent to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid32">32</a>].</p><p>The treatment of bleeding associated with DOACs is discussed separately. (See  <a class="medical medical_review" href="/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a>.)</p><p class="headingAnchor" id="H3260855259"><span class="h2">Risk factors and predictive tools</span><span class="headingEndMark"> — </span>Risk factors for bleeding on anticoagulation therapy in patients with VTE are presented in the Table  (<a class="graphic graphic_table graphicRef97160" href="/d/graphic/97160.html" rel="external">table 11</a>).</p><p>Tools are available for estimating the risk of bleeding on anticoagulation including the HAS-BLED score (<a class="calc calc_professional" href="/d/html/94104.html" rel="external">calculator 2</a>). The HAS-BLED score has been validated in patients anticoagulated for VTE [<a href="#rid85">85-87</a>], although as a clinical score, the predictive value for bleeding risk in a particular patient is modest. Absolute and relative contraindications to anticoagulation as well as scoring systems that estimate the risk of bleeding are discussed separately. (See  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation", section on 'Bleeding risk'</a> and  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Patients at high risk of bleeding'</a> and  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Mitigating bleeding risk'</a> and  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'Assessing the risk of bleeding'</a> and  <a class="medical medical_review" href="/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>.)</p><p>The SAMeTT2R2 score is used to help identify those patients less likely to do well on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> in relation to anticoagulation control, hence allowing these patients to have more frequent INR checks or to consider a NOAC [<a href="#rid88">88</a>].</p><p>While abnormal uterine bleeding (AUB) is not a contraindication per se to anticoagulation, retrospective data suggest that anticoagulation can increase the rate of AUB and have a negative impact on the quality of life [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H125666134"><span class="h1">RECURRENT VENOUS THROMBOEMBOLISM ON ANTICOAGULATION</span><span class="headingEndMark"> — </span>Some patients may have a thromboembolic event while receiving anticoagulation. In these patients, the diagnosis of recurrence should be confirmed with radiologic testing (eg, repeat compression ultrasonography or CT pulmonary angiography). Subtherapeutic anticoagulation is the most common reason, but several other etiologies including ongoing thrombotic stimulus (eg, cancer) may be present. Occasionally no obvious cause is evident (idiopathic). The causes and management of suspected recurrence are discussed separately. (See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Management of recurrence on therapy'</a> and  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy", section on 'Management of recurrence'</a>.)</p><p class="headingAnchor" id="H1585725916"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113663.html" rel="external">"Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114614.html" rel="external">"Society guideline links: Anticoagulation"</a>.)</p><p class="headingAnchor" id="H28215487"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15362.html" rel="external">"Patient education: Deep vein thrombosis (blood clot in the leg) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/693.html" rel="external">"Patient education: Deep vein thrombosis (DVT) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/689.html" rel="external">"Patient education: Warfarin (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H28215493"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nomenclature</strong> – Long-term (maintenance) anticoagulant therapy for venous thromboembolism (VTE) is administered beyond the initial period of anticoagulation for a finite period of 3 to 12 months. (See <a class="local">'Nomenclature'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Options for long-term anticoagulation include oral anticoagulants (ie, factor Xa inhibitors, direct thrombin inhibitors, and <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) and parenteral subcutaneous anticoagulants (low molecular weight [LMW] heparin and <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a>). While the oral factor Xa and direct thrombin inhibitors are typically preferred, choosing among these options frequently depends upon clinician experience and availability, the risks of bleeding, patient comorbidities and preferences, cost, and convenience  (<a class="graphic graphic_table graphicRef91199" href="/d/graphic/91199.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef107541" href="/d/graphic/107541.html" rel="external">table 1</a>). In general, the following applies (see <a class="local">'Selection of agent'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>First-line agents</strong> – For most nonpregnant patients who do not have severe renal insufficiency (ie, creatinine clearance [CrCl] &gt;30 mL/minute) or active cancer, we recommend a direct oral anticoagulant (DOAC; ie, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, or <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>) rather than other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). In general, these agents have similar efficacy to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and a lower risk of bleeding. DOACs are <strong>not</strong> suitable for the treatment of hemodynamically unstable pulmonary embolism (PE), massive iliofemoral deep vein thrombosis (DVT), those who are pregnant, or those with severe renal insufficiency. Dosing of these agents is individualized. (See <a class="local">'Selection of agent'</a> above and <a class="local">'Direct thrombin and factor Xa inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Second-line agents</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> is an alternative for patients in whom there is concern about the poor availability of reversal agents and in those with severe renal insufficiency (although <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> may be used in those with a CrCl &lt;15 mL/minute). Warfarin should be overlapped with heparin until the international normalized ratio is therapeutic for 24 hours. (See <a class="local">'Selection of agent'</a> above and <a class="local">'Warfarin'</a> above and <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>LMW heparin and <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> are also effective treatments and may be preferred in some special populations without severe renal failure. Dosing requirements are product specific, and no laboratory monitoring is required. (See <a class="local">'Selection of agent'</a> above and <a class="local">'Low molecular weight heparin'</a> above and <a class="local">'Fondaparinux'</a> above and <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Anticoagulant therapy in patients who are pregnant or have active malignancy, in whom LMW heparin is the long-term agent of choice, and patients with heparin-induced thrombocytopenia, in whom heparin should be avoided, are discussed separately. (See <a class="local">'Special populations'</a> above and  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a> and  <a class="medical medical_review" href="/d/html/1350.html" rel="external">"Venous thromboembolism in pregnancy and postpartum: Treatment"</a> and  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a> and  <a class="medical medical_review" href="/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration</strong> – For patients with a first episode of acute VTE, the <strong>duration</strong> of anticoagulant therapy should be individualized according to the presence or absence of provoking events and risk factors, while taking into account the estimated risk for recurrence and bleeding and the individual patient's preferences and values  (<a class="graphic graphic_table graphicRef107543" href="/d/graphic/107543.html" rel="external">table 8</a> and <a class="graphic graphic_table graphicRef107542" href="/d/graphic/107542.html" rel="external">table 7</a>). In general, the following applies (see <a class="local">'Duration of treatment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Minimum duration</strong> – For most patients with proximal DVT and/or symptomatic PE, we recommend anticoagulation for a minimum of three months rather than for shorter periods (eg, four or six weeks), regardless of whether or not the event was provoked (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). The optimal duration of therapy for patients with distal DVT and small subsegmental PE is less certain; in general, we treat these patients for three months as well.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extending anticoagulation</strong> – For patients with a provoked episode of VTE who have persistent but reversible risk factors (eg, continued estrogen use, prolonged immobility following trauma), we suggest <strong>extending anticoagulation for a finite period</strong> until the risk factor is resolved, rather than stopping anticoagulation at three months (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">Select patients benefit from <strong>indefinite</strong> anticoagulation and are discussed separately. (See  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Switching anticoagulants</strong> – Therapeutic anticoagulation should be ensured during transition periods. The strategy used depends upon the anticoagulants used for such periods. Interruptions during the first three months should be minimized due to the high risk of recurrent thrombosis during this period. (See <a class="local">'Agents for long-term anticoagulation'</a> above and <a class="local">'Switching anticoagulants during therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – All patients with acute DVT who are anticoagulated, especially those on factor Xa and direct thrombin inhibitors and those &gt;75 years, should be monitored clinically for recurrence and bleeding, as well as for the signs and symptoms of conditions that may affect the half-life of the anticoagulant used (eg, renal failure, weight gain or loss) and adverse effects of the medications (eg, skin necrosis, thrombocytopenia, osteoporosis). (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding</strong> – Major bleeding rates on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and LMW heparin during the first three months of anticoagulant therapy are low (less than 2 percent). Factor Xa and direct thrombin inhibitors have lower bleeding rates compared to warfarin; however, these rates may not reflect those in clinical practice and reversal of the anticoagulant effect is considerably more complex than that for warfarin. (See <a class="local">'Risk of bleeding'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Raja AS, Greenberg JO, Qaseem A, et al. Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2015; 163:701.</a></li><li><a class="nounderline abstract_t">Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4:4693.</a></li><li><a class="nounderline abstract_t">Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J 2019; 54.</a></li><li><a class="nounderline abstract_t">Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest 2021; 160:e545.</a></li><li><a class="nounderline abstract_t">Neumann I, Izcovich A, Aguilar R, et al. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America. Blood Adv 2023; 7:3005.</a></li><li><a class="nounderline abstract_t">Kearon C, Ageno W, Cannegieter SC, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016; 14:1480.</a></li><li><a class="nounderline abstract_t">Husted S, de Caterina R, Andreotti F, et al. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014; 111:781.</a></li><li><a class="nounderline abstract_t">MacLean S, Mulla S, Akl EA, et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e1S.</a></li><li><a class="nounderline abstract_t">Vlazny DT, Pasha AK, Kuczmik W, et al. Outcome of anticoagulation in isolated distal deep vein thrombosis compared to proximal deep venous thrombosis. J Thromb Haemost 2021; 19:2206.</a></li><li><a class="nounderline abstract_t">EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499.</a></li><li><a class="nounderline abstract_t">EINSTEIN–PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366:1287.</a></li><li><a class="nounderline abstract_t">Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369:799.</a></li><li><a class="nounderline abstract_t">Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369:1406.</a></li><li><a class="nounderline abstract_t">Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342.</a></li><li><a class="nounderline abstract_t">Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129:764.</a></li><li><a class="nounderline abstract_t">Martin KA, Beyer-Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021; 19:1874.</a></li><li><a class="nounderline abstract_t">Coons JC, Albert L, Bejjani A, Iasella CJ. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism. Pharmacotherapy 2020; 40:204.</a></li><li><a class="nounderline abstract_t">Crouch A, Ng TH, Kelley D, et al. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity. Pharmacotherapy 2022; 42:119.</a></li><li><a class="nounderline abstract_t">Jun M, Lix LM, Durand M, et al. Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study. BMJ 2017; 359:j4323.</a></li><li><a class="nounderline abstract_t">Wang X, Ma Y, Hui X, et al. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis. Cochrane Database Syst Rev 2023; 4:CD010956.</a></li><li><a class="nounderline abstract_t">Li M, Li J, Wang X, et al. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism. Cochrane Database Syst Rev 2023; 4:CD010957.</a></li><li><a class="nounderline abstract_t">Cheung YW, Middeldorp S, Prins MH, et al. Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thromb Haemost 2016; 116:733.</a></li><li><a class="nounderline abstract_t">Søgaard M, Nielsen PB, Skjøth F, et al. Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism. Am J Med 2018; 131:787.</a></li><li><a class="nounderline abstract_t">Weycker D, Li X, Wygant GD, et al. Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice. Thromb Haemost 2018; 118:1951.</a></li><li><a class="nounderline abstract_t">Verhamme P, Wells PS, Segers A, et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost 2016; 116:747.</a></li><li><a class="nounderline abstract_t">Goldhaber SZ, Schellong S, Kakkar A, et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost 2016; 116:714.</a></li><li><a class="nounderline abstract_t">Goldhaber SZ, Eriksson H, Kakkar A, et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™. Vasc Med 2016; 21:506.</a></li><li><a class="nounderline abstract_t">Dawwas GK, Brown J, Dietrich E, Park H. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol 2019; 6:e20.</a></li><li><a class="nounderline abstract_t">Aryal MR, Gosain R, Donato A, et al. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv 2019; 3:2381.</a></li><li><a class="nounderline abstract_t">Dawwas GK, Leonard CE, Lewis JD, Cuker A. Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. Ann Intern Med 2022; 175:20.</a></li><li><a class="nounderline abstract_t">Frost C, Song Y, Barrett YC, et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol 2014; 6:179.</a></li><li><a class="nounderline abstract_t">Douros A, Basedow F, Cui Y, et al. Effectiveness and Safety of Direct Oral Anticoagulants Among Octogenarians with Venous Thromboembolism: An International Multidatabase Cohort Study. Am J Med 2023; 136:79.</a></li><li><a class="nounderline abstract_t">Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.</a></li><li><a class="nounderline abstract_t">Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e152S.</a></li><li><a class="nounderline abstract_t">Baglin T, Bauer K, Douketis J, et al. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost 2012; 10:698.</a></li><li><a class="nounderline abstract_t">Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301:855.</a></li><li><a class="nounderline abstract_t">Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 1992; 340:873.</a></li><li><a class="nounderline abstract_t">Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2:515.</a></li><li><a class="nounderline abstract_t">Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74:606.</a></li><li><a class="nounderline abstract_t">Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336:393.</a></li><li><a class="nounderline abstract_t">Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332:1661.</a></li><li><a class="nounderline abstract_t">Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011; 342:d3036.</a></li><li><a class="nounderline abstract_t">Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103:2453.</a></li><li><a class="nounderline abstract_t">Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152:578.</a></li><li><a class="nounderline abstract_t">BARRITT DW, JORDAN SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; 1:1309.</a></li><li><a class="nounderline abstract_t">Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.</a></li><li><a class="nounderline abstract_t">Andras A, Sala Tenna A, Stewart M. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2017; 7:CD002001.</a></li><li><a class="nounderline abstract_t">Hull RD, Pineo GF, Brant RF, et al. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007; 120:72.</a></li><li><a class="nounderline abstract_t">Daskalopoulos ME, Daskalopoulou SS, Liapis CD. Tinzaparin in long-term treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2007; 34:353.</a></li><li><a class="nounderline abstract_t">Hull RD, Pineo GF, Brant R, et al. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med 2009; 122:762.</a></li><li><a class="nounderline abstract_t">Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med 2011; 124:756.</a></li><li><a class="nounderline abstract_t">Brandao GM, Junqueira DR, Rollo HA, Sobreira ML. Pentasaccharides for the treatment of deep vein thrombosis. Cochrane Database Syst Rev 2017; 12:CD011782.</a></li><li><a class="nounderline abstract_t">Kearon C, Ginsberg JS, Julian JA, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006; 296:935.</a></li><li><a class="nounderline abstract_t">Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol 2013; 32:111.</a></li><li><a class="nounderline abstract_t">Ageno W, Bertù L, Bucherini E, et al. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. BMJ 2022; 379:e072623.</a></li><li><a class="nounderline abstract_t">Franco L, Giustozzi M, Agnelli G, Becattini C. Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. J Thromb Haemost 2017; 15:1142.</a></li><li><a class="nounderline abstract_t">Prandoni P, Prins MH, Lensing AW, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 2009; 150:577.</a></li><li><a class="nounderline abstract_t">Garcia D, Alexander JH, Wallentin L, et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood 2014; 124:3692.</a></li><li><a class="nounderline abstract_t">Gladstone DJ, Geerts WH, Douketis J, et al. How to Monitor Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Practice Tool Endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society. Ann Intern Med 2015; 163:382.</a></li><li><a class="nounderline abstract_t">Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e44S.</a></li><li><a class="nounderline abstract_t">Garcia P, Ruiz W, Loza Munarriz C. Warfarin initiation nomograms for venous thromboembolism. Cochrane Database Syst Rev 2013; :CD007699.</a></li><li><a class="nounderline abstract_t">Davidson BL, Verheijen S, Lensing AW, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med 2014; 174:947.</a></li><li><a class="nounderline abstract_t">Robertson L, Yeoh SE, Stansby G, Agarwal R. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in patients with unprovoked VTE. Cochrane Database Syst Rev 2015; :CD010837.</a></li><li><a class="nounderline abstract_t">Fox BD, Kahn SR, Langleben D, et al. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012; 345:e7498.</a></li><li><a class="nounderline abstract_t">van der Hulle T, Kooiman J, den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12:320.</a></li><li><a class="nounderline abstract_t">Castellucci LA, Cameron C, Le Gal G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ 2013; 347:f5133.</a></li><li><a class="nounderline abstract_t">Castellucci LA, Cameron C, Le Gal G, et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA 2014; 312:1122.</a></li><li><a class="nounderline abstract_t">Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124:2450.</a></li><li><a class="nounderline abstract_t">Vespa PM. Oral anticoagulants and the risk of intracranial hemorrhage. JAMA 2014; 312:2562.</a></li><li><a class="nounderline abstract_t">Raccah BH, Perlman A, Danenberg HD, et al. Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure: Systematic Review and Meta-Analysis of Randomized Trials. Chest 2016; 149:1516.</a></li><li><a class="nounderline abstract_t">Inohara T, Xian Y, Liang L, et al. Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. JAMA 2018; 319:463.</a></li><li><a class="nounderline abstract_t">Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368:1272.</a></li><li class="breakAll">US Food and Drug Administration (FDA). FDA drug safety communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with dabigatran compared to warfarin. http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm (Accessed on July 03, 2014).</li><li><a class="nounderline abstract_t">McConeghy K, Bress A, Wing C. Reports of bleeding-related fatalities with dabigatran and warfarin: An analysis using the Food and Drug Administration adverse events reporting system. J Am Coll Cardiol 2013; 61.</a></li><li class="breakAll">Institute for Safe Medication Practices. QuarterWatch Reports. http://www.ismp.org/quarterwatch/pdfs/2012Q2.pdf (Accessed on July 03, 2014).</li><li><a class="nounderline abstract_t">Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 2014; 62:857.</a></li><li><a class="nounderline abstract_t">McConeghy KW, Bress A, Qato DM, et al. Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. Pharmacotherapy 2014; 34:561.</a></li><li><a class="nounderline abstract_t">Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363.</a></li><li><a class="nounderline abstract_t">Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366:864.</a></li><li><a class="nounderline abstract_t">Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011; 123:1436.</a></li><li><a class="nounderline abstract_t">Kucher N, Aujesky D, Beer JH, et al. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER). Thromb Haemost 2016; 116:472.</a></li><li><a class="nounderline abstract_t">Barra ME, Fanikos J, Connors JM, et al. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. Am J Med 2016; 129:1198.</a></li><li><a class="nounderline abstract_t">Ray WA, Chung CP, Murray KT, et al. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. JAMA 2018; 320:2221.</a></li><li><a class="nounderline abstract_t">Ingason AB, Hreinsson JP, Ágústsson AS, et al. Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants : A Nationwide Propensity Score-Weighted Study. Ann Intern Med 2021; 174:1493.</a></li><li><a class="nounderline abstract_t">Brown JD, Goodin AJ, Lip GYH, Adams VR. Risk Stratification for Bleeding Complications in Patients With Venous Thromboembolism: Application of the HAS-BLED Bleeding Score During the First 6 Months of Anticoagulant Treatment. J Am Heart Assoc 2018; 7.</a></li><li><a class="nounderline abstract_t">Rief P, Raggam RB, Hafner F, et al. Calculation of HAS-BLED Score Is Useful for Early Identification of Venous Thromboembolism Patients at High Risk for Major Bleeding Events: A Prospective Outpatients Cohort Study. Semin Thromb Hemost 2018; 44:348.</a></li><li><a class="nounderline abstract_t">Kooiman J, van Hagen N, Iglesias Del Sol A, et al. The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. PLoS One 2015; 10:e0122520.</a></li><li><a class="nounderline abstract_t">Palareti G, Antonucci E, Lip GY, et al. The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study. Thromb Haemost 2016; 115:1101.</a></li><li><a class="nounderline abstract_t">de Jong CMM, Blondon M, Ay C, et al. Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism. Blood 2022; 140:1764.</a></li></ol></div><div id="topicVersionRevision">Topic 95395 Version 91.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26414967" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33007077" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31473594" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34352278" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36929813" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27428935" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24658395" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315262" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34060224" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Outcome of anticoagulation in isolated distal deep vein thrombosis compared to proximal deep venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21128814" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Oral rivaroxaban for symptomatic venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22449293" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23808982" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Oral apixaban for the treatment of acute venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23991658" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19966341" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Dabigatran versus warfarin in the treatment of acute venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24344086" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34259389" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31968126" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34904263" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29042362" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37058421" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37057837" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27583311" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29476744" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30357780" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27440518" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27411591" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27807306" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™II, and RE-MEDY™.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30558988" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31405948" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34871048" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25419161" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36150513" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effectiveness and Safety of Direct Oral Anticoagulants Among Octogenarians with Venous Thromboembolism: An International Multidatabase Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574265" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315259" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22332937" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/384248" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1357297" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2863541" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8584992" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9010144" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7760866" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21610040" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11369685" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439576" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13797091" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315268" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28737834" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17208082" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17574456" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Tinzaparin in long-term treatment of deep venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19635277" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21787905" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29199766" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pentasaccharides for the treatment of deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16926353" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24402349" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prevention and treatment of venous thromboembolism--International Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36520715" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28316124" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414836" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25320240" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26121536" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : How to Monitor Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Practice Tool Endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315269" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23839808" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Warfarin initiation nomograms for venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24733305" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25749503" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in patients with unprovoked VTE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23150473" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24330006" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23996149" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25226478" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25150296" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25514305" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Oral anticoagulants and the risk of intracranial hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26836922" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure: Systematic Review and Meta-Analysis of Randomized Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29372247" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23484796" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Dabigatran and postmarketing reports of bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23484796" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Dabigatran and postmarketing reports of bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Reports of bleeding-related fatalities with dabigatran and warfarin: An analysis using the Food and Drug Administration adverse events reporting system</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Reports of bleeding-related fatalities with dabigatran and warfarin: An analysis using the Food and Drug Administration adverse events reporting system</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24786913" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24644100" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576658" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22375994" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Bleeding risk with dabigatran in the frail elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21464059" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Dabigatran etexilate: a new oral thrombin inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27346301" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27341955" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30512099" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34633836" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants : A Nationwide Propensity Score-Weighted Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29514808" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Risk Stratification for Bleeding Complications in Patients With Venous Thromboembolism: Application of the HAS-BLED Bleeding Score During the First 6 Months of Anticoagulant Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29165742" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Calculation of HAS-BLED Score Is Useful for Early Identification of Venous Thromboembolism Patients at High Risk for Major Bleeding Events: A Prospective Outpatients Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25905638" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26819229" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35925686" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
